Auris Medical's ear tinnitus drug Keyzilen fails to meet co-primary endpoints in phase 3 trial
Auris Medical announced top-line results from the Phase 3 TACTT2 trial with KeyzilenTM (AM-101) in acute inner ear tinnitus.
The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo.
Click on this link for more information.
